Last Updated: November 8, 2026

CLINICAL TRIALS PROFILE FOR GALLIUM GA-68 EDOTREOTIDE

« Back to Dashboard

All Clinical Trials for GALLIUM GA-68 EDOTREOTIDE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03001349 ↗	68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors	Terminated	National Cancer Institute (NCI)	Early Phase 1	2017-05-16	This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT03001349 ↗	68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors	Terminated	M.D. Anderson Cancer Center	Early Phase 1	2017-05-16	This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT06091748 ↗	Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors	Not yet recruiting	Jiangsu HengRui Medicine Co., Ltd.	Phase 3	2023-11-01	This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for GALLIUM GA-68 EDOTREOTIDE

Condition Name

Chart
Table

Condition Name for GALLIUM GA-68 EDOTREOTIDE
Intervention	Trials
Multiple Endocrine Neoplasia Type 1	1
Neuroendocrine Neoplasm	1
Somatostatin Positive Neoplastic Cells Present	1
Von Hippel-Lindau Syndrome	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for GALLIUM GA-68 EDOTREOTIDE
Intervention	Trials
Neuroendocrine Tumors	2
Multiple Endocrine Neoplasia Type 1	1
Multiple Endocrine Neoplasia	1
Meningioma	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for GALLIUM GA-68 EDOTREOTIDE

Trials by Country

Map
Table

Trials by Country for GALLIUM GA-68 EDOTREOTIDE
Location	Trials
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for GALLIUM GA-68 EDOTREOTIDE
Location	Trials
Texas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for GALLIUM GA-68 EDOTREOTIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for GALLIUM GA-68 EDOTREOTIDE
Clinical Trial Phase	Trials
Phase 3	1
Early Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for GALLIUM GA-68 EDOTREOTIDE
Clinical Trial Phase	Trials
Not yet recruiting	1
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GALLIUM GA-68 EDOTREOTIDE

Sponsor Name

Chart
Table

Sponsor Name for GALLIUM GA-68 EDOTREOTIDE
Sponsor	Trials
National Cancer Institute (NCI)	1
M.D. Anderson Cancer Center	1
Jiangsu HengRui Medicine Co., Ltd.	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for GALLIUM GA-68 EDOTREOTIDE
Sponsor	Trials
NIH	1
Other	1
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.